María del Rosario
García Campelo

Foto de María del Rosario

Foto de University of Texas MD Anderson Cancer Center

University of Texas MD Anderson Cancer Center

Houston, Estados Unidos

Publicacións en colaboración con investigadores/as de University of Texas MD Anderson Cancer Center (4)

2021

Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials
Cancer Medicine, Vol. 10, Núm. 17, pp. 5748-5756

2020

Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
The Lancet Oncology, Vol. 21, Núm. 11, pp. 1413-1422

2012

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial
The Lancet Oncology, Vol. 13, Núm. 3, pp. 239-246

2011

Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non-Small-Cell Lung Cancer Patients with EGFR Mutations
Clinical Cancer Research, Vol. 17, Núm. 5, pp. 1160-1168

Proxecto CRIS desenvolto en colaboración coa Fundación Dialnet (Universidad de La Rioja)